Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-12-17

Clinical Trial Update: Nepafenac 0.3% Two Study [Phase 2]

View source ↗

Summary

Two Phase 2 studies of nepafenac 0.3% for cataract have completed, and results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ILEVRO (nepafenac)

Snippet

Sponsor: Alcon Research | Conditions: Cataract | Phase 2 | Status: COMPLETED | Results posted: 2012-12-17